By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...

The U.S. Centers for Disease Control and Prevention's outside expert panel will convene on Tuesday after a nearly two-month delay and expects to review guidelines for several vaccines including ...

Vaccine makers targeting COVID-19 to measles will come under investor scrutiny on Tuesday as a group of independent experts at the CDC are scheduled to meet for the first time to review U.S.

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary ...

A two-day meeting of the Advisory Committee on Immunization Practices (ACIP), which was originally scheduled for February but was ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy wanes ...

Tracy Beth Hoeg, a sports medicine physician and epidemiologist who opposed key U.S. health policies during the COVID-19 ...

GSK has also sued Pfizer for patent infringement in the U.S. over technology in Pfizer's blockbuster COVID-19 vaccine Comirnaty. That case is still ongoing.